3533 or 202/357–3532. Applications must be mailed to the above address or hand-delivered to the Office of Grants Management, Room 4604, One Massachusetts Avenue, NW., Washington, DC 20001. Application kits and instructions for electronic mailing of grant applications are available at *http://www.aoa.gov/egrants.*

Dated: April 2, 2003.

Josefina G. Carbonell,

Assistant Secretary for Aging.

[FR Doc. 03–8418 Filed 4–4–03; 8:45 am]

BILLING CODE 4154–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Availability of Government-Owned Inventions for Licensing

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services.

ACTION: Notice.

SUMMARY: The inventions named in this notice are owned by agencies of the United States Government. In accordance with 35 U.S.C. 209(e) and to achieve expeditious commercialization of results of federally funded research and development, the inventions are available for licensing in the United States (U.S.). Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to Thomas E. O'Toole, M.P.H., Deputy Director, Technology Transfer Office, Centers for Disease Control and Prevention (CDC), Mailstop K–79, 1600 Clifton Road, Atlanta, GA 30333, telephone (770) 488–8611; facsimile (770) 488–8615; or e-mail *tto@cdc.gov*. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.

Automated Microscopic Image Acquisition, Compositing, and Display (CDC Ref. I–019–00/0), U.S. Patent SN: 10/001,268.

Single Vial Reconstitution System for Lyophilized Vaccines and Other Pharmaceuticals (CDC Ref. I–005–02/0), U.S. Patent SN: 60/391,862.

Molecular Identification of Aspergillus Species (CDC Ref. I–006–02/0), U.S. Patent SN: 60/381,463.

Integration of Gene Expression Data and Non-Gene Data (CDC Ref. I–024–02/0), U.S. Patent SN: 60/429,920.

Measurement of Total Reactive Isocyanate Groups in Samples Using Bifunctional Nucleophiles Such as 1,8-Diaminonapthalene (DAN) (CDC Ref. I–034–02/0), U.S. Patent SN: 60/429,963.

Dated: March 31, 2003.

James D. Seligman,

Associate Director for Program Services, Centers for Disease Control and Prevention (CDC).

[FR Doc. 03–8321 Filed 4–4–03; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Prospective Grant of Exclusive License: Diagnostics of Fungal Infections

AGENCY: Technology Transfer Office, Centers for Disease Control and Prevention (CDC), Department of Health and Human Services.

ACTION: Notice.

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention (CDC), Technology Transfer Office, Department of Health and Human Services (DHHS), is contemplating the grant of a worldwide, limited field of use, exclusive license to practice the inventions embodied in the patent and patent applications referred to below to Transgenomic, Inc. (Transgenomic) having a place of business in Omaha, Nebraska. The patent rights in these inventions have been assigned to the government of the United States of America. The patent and patent applications to be licensed are:

Title: Rapid and Sensitive Method for Detecting *Histoplasma capsulatum.*

U.S. Patent Application Serial No.: 09/673,298.

Filing Date: 1/12/2001.

Domestic Status: Patent No.: 6,469,156.

Issue Date: 10/22/2002.

Title: Nucleic Acids for Detecting *Aspergillus* Species and Other Filamentous Fungi.

U.S. Patent Application Serial No.: 09/423,233.

Filing Date: 6/27/2000.

Domestic Status: 6,372,430.

Issue Date: 4/16/2002.

Title: Molecular Identification of *Aspergillus* Species.

U.S. Patent Application Serial No.: 60/381,463.

Filing Date: 5/17/2002.

Domestic Status: Pending.

Issue Date: N/A.

Title: Nucleic Acids for the Identification of Fungi and Methods for Using the Same.

U.S. Patent Application Serial No.: 60/325,241.

Filing Date: 9/26/2001.

Domestic Status: Pending.

Issue Date: N/A.

Title: Nucleic Acids of the M Antigen Gene of Histoplasma Capsulatum, Antigens, Vaccines, and Antibodies.

U.S. Patent Application Serial No.: 09/674,195.

Filing Date: 10/10/2000.

Domestic Status: Pending.

Issue Date: N/A.

Title: Nucleic Acids for Detecting *Fusarium* Species and Other Filamentous Fungi.

U.S. Patent Application Serial No.: 10/046,955.

Filing Date: 1/14/2002.

Domestic Status: Pending.

Issue Date: N/A.

Title: Nucleic Acid Probes for Detecting *Candida* Species.

U.S. Patent Application Serial No.: 08/903,446.

Filing Date: 7/30/1997.

Domestic Status: 6,242,178.

Issue Date: 6/5/2001.

Title: Nucleic Acid Probes for *Candida Parapsilosis* Methods for Detecting Candidiasis in Blood.

U.S. Patent Application Serial No.: 08/429,520.

Filing Date: 4/26/1995.

Domestic Status: 5,688,644.

Issue Date: 11/18/1997.

Title: Nucleic Acid Sequences and Methods for Detecting *Candida tropicalis* in Blood.

U.S. Patent Application Serial No.: 08/429,522.

Filing Date: 4/26/1995.

Domestic Status: 5,645,992.

Issue Date: 7/8/1997.

Title: Nucleic Acid Probes and Methods for Detecting *Candida krusei* Cells in Blood.

U.S. Patent Application Serial No.: 08/429,532.

Filing Date: 4/26/1995.

Domestic Status: 5,635,353.

Issue Date: 6/3/1997.

Title: Nucleic Acid Probes and Methods for Detecting *Candida glabrata* DNA in Blood.

U.S. Patent Application Serial No.: 08/429,523.

Filing Date: 4/26/1995.

Domestic Status: 5,631,132.

Issue Date: 5/20/1997.

Title: Nucleic Acid Probes and Methods for Detecting *Candida* DNA Cells in Blood.

U.S. Patent Application Serial No.: 08/065,845.

Filing Date: 5/20/1993.

Domestic Status: 5,426,027.

Issue Date: 6/20/1995.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.

Specific DNA (oligonucleotide) probes have been developed for a wide variety of systemic disease causing fungi, including *Histoplasma capsulatum, Aspergillus* species, *Candida* species, *Fusarium* species, and others. A probe has been developed for identification of all dimorphic fungi. These probes can be used for the rapid identification of fungal pathogens and for the diagnosis of mycotic diseases.

ADDRESSES: Requests for a copy of these patent applications, inquiries, comments, and other materials relating to the contemplated license should be directed to Andrew Watkins, Director, Technology Transfer Office, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, Mailstop K–79, Atlanta, GA 30341, telephone: (770) 488–8610; facsimile: (770) 488–8615. Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by CDC within sixty days of this notice will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. A signed Confidential Disclosure Agreement will be required to receive a copy of any pending patent application.

Dated: March 31, 2003.

James D. Seligman,

Associate Director for Program Services, Centers for Disease Control and Prevention (CDC).

[FR Doc. 03–8322 Filed 4–4–03; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 99F–2999]

Ciba Specialty Chemicals; Withdrawal of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of a food additive petition (FAP 9B4686) proposing that the food additive regulations be amended to provide for the safe use of benzenepropanoic acid, 3,5- bis(1,1-dimethylethyl)-4-hydroxy-, C7-C9-branched alkyl esters as an antioxidant and/or stabilizer for adhesives.

FOR FURTHER INFORMATION CONTACT: Mark Hepp, Center for Food Safety and Applied Nutrition (HFS–275), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740–3858, 202–418–3098.

SUPPLEMENTARY INFORMATION: In a notice published in the **Federal Register** of September 7, 1999 (64 FR 48654), FDA announced that a food additive petition (FAP 9B4686) had been filed by Ciba Specialty Chemicals, 540 White Plains Rd., P.O. Box 2005, Tarrytown, NY 10591–9005. The petition proposed to amend the food additive regulations in § 178.2010 Antioxidants and/or stabilizers for polymers (21 CFR 178.2010) to provide for the safe use of benzenepropanoic acid, 3,5- bis(1,1-dimethylethyl)-4-hydroxy-, C7-C9-branched alkyl esters as an antioxidant and/or stabilizer for adhesives. Ciba Specialty Chemicals has now withdrawn the petition without prejudice to a future filing (21 CFR 171.7).

Dated: March 20, 2003.

Alan M. Rulis,

Director, Office of Food Additive Safety, Center for Food Safety and Applied Nutrition.

[FR Doc. 03–8335 Filed 4–4–03; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

[CFDA Number 93.110B]

Maternal and Child Health Federal Set-Aside Program; Special Projects of Regional and National Significance; Comprehensive Hemophilia Diagnostic and Treatment Centers; Regional Project Grant

AGENCY: Health Resources and Services Administration, HHS.

ACTION: Notice of availability of funds.

SUMMARY: The Health Resources and Services Administration (HRSA) announces that $360,000 in fiscal year (FY) 2003 funds is available to fund one grant to establish a regional network of hemophilia treatment centers (HTCs) in the Maternal and Child Health Bureau Hemophilia Program, Region IV North (Kentucky, North Carolina, South Carolina, and Tennessee) to provide comprehensive care for people with hemophilia and other congenital bleeding disorders and their families in the diagnosis and treatment of hemophilia and other bleeding disorders. This grant will be awarded for a 2-year period, subject to satisfactory progress and the availability of funds.

DATES: Applications must be received in the HRSA Grant Application Center (GAC) at the address below by the close of business, May 8, 2003. Applications will meet the deadline if they are either: (1) Received on or before the deadline date; or (2) postmarked on or before the deadline date, and received in time for submission to the objective review panel. A legible, dated receipt from a commercial carrier or U.S. Postal Service will be accepted instead of a postmark. Private metered postmarks will not be accepted as proof of timely mailing.

ADDRESSES: To receive a complete application kit, applicants may telephone the HRSA Grants Application Center at 1–877–477–2123 (1–877–HRSA–123) and present the announcement number HRSA 03–084 and announcement code HTC or register on-line at: *http://www.mchb.hrsa.gov/grants/.* All applications should be mailed or delivered to: Grants Management Officer (MCHB), HRSA Grants Application Center, 901 Russell Avenue, Suite 450, Gaithersburg, Maryland, 20879, telephone: 1–877–HRSA–123 (1–877–477–2123), e-mail: *hrsagac@hrsa.gov.*